An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed

Bristol-Myers Squibb (BMS) logo

Bristol-Myers Squibb (BMS)

Status and phase

Terminated
Phase 1

Conditions

Advanced Cancer

Treatments

Drug: BMS-986299
Biological: Ipilimumab
Biological: Nivolumab

Study type

Interventional

Funder types

Industry

Identifiers

NCT03444753
CA039-001

Details and patient eligibility

About

The purpose of this study is to determine whether BMS-986299 both by itself and in combination with Nivolumab and Ipilimumab is safe and tolerable in the treatment of advanced solid tumors. In addition, the ability of study drugs to stimulate an immune response against cancer will be investigated.

Enrollment

82 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Histologically or cytologically confirmed advanced/metastatic solid tumor and refractory to or intolerant of existing therapy(ies) known to provide clinical benefit for the condition of the participant IO therapy resistant or insensitive tumors Have at least 2 tumor lesions accessible for biopsy Eastern Cooperative Oncology Group Performance Status of 0 or 1

Exclusion criteria

Primary CNS malignancy Participants with other active malignancy requiring concurrent intervention Uncontrolled or significant cardiovascular disease Other protocol-defined inclusion/exclusion criteria apply

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

82 participants in 2 patient groups

Arm A
Experimental group
Description:
BMS-986299
Treatment:
Drug: BMS-986299
Arm B
Experimental group
Description:
BMS-986299 in combination with nivolumab and ipilimumab
Treatment:
Biological: Nivolumab
Biological: Ipilimumab
Drug: BMS-986299

Trial contacts and locations

9

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems